{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:44:40Z","timestamp":1791582280911,"version":"4.3.4"},"reference-count":33,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"\n Background & objectives<\/jats:title>\n Evidence suggests that higher doses of rifampicin aid in faster culture conversion, but its effects on unfavourable outcomes are unclear. We aimed to synthesise evidence on the efficacy and safety of high-dose rifampicin (>15 mg\/kg) containing anti-tuberculosis regimen compared to a regimen with standard dose of rifampicin in adults with pulmonary tuberculosis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We searched for studies from MEDLINE, Embase, Web of Science, Google Scholar, and the Cochrane Library without geographical restriction. We included randomised controlled trials that evaluated high-dose rifampicin (>15 mg\/kg for 8 wk) with a six-month duration. Our outcomes of interest were sputum conversion at eight wk, mortality, treatment failure at six months, Grade 3 and Grade 4 hepatotoxicity, and adverse events leading to treatment discontinuation. Two authors independently screened titles, abstracts, and full texts and extracted data. We performed a meta-analysis using the RevMan web software as per the Cochrane Handbook for Systematic Reviews of Interventions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Out of 3950 articles screened, we included nine for meta-analysis. High-dose rifampicin (\u226515 mg\/kg) showed little benefit compared to the standard dose for sputum conversion at eight wk [(83%\n vs<\/jats:italic>\n . 78%, Relative risk (RR) 1.05 (95% confidence interval (CI): 1.0-1.09), Number needed to treat (NNT)-24)] and this benefit was higher as the rifampicin dose increased [20-30 mg RR: 1.07 (95% CI 1.02-1.14), NNT-17]; >30 mg RR: 1.12 (95% CI 1.04 -1.20) NNT-9]. However, treatment failure and mortality showed no benefit with high-dose rifampicin. Grade 3 and 4 hepatotoxicity and treatment discontinuation due to toxicity had a dose-response relationship and were significantly higher in the more than 30 mg\/kg group [RR: 4.01 (95%CI 1.75-9.19), Number needed to harm -20].\n <\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions<\/jats:title>\n High doses of rifampicin (\u226515 mg\/kg) increased the rate of sputum culture conversion after two months of the intensive phase. There was no difference in mortality and treatment failure between high-dose rifampicin and standard arms. In the subgroup analysis, the 20-30 mg\/kg dose exhibited a beneficial effect in sputum conversion with no significant risk of hepatotoxicity and adverse drug reactions (ADR) leading to treatment discontinuation. This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/ijmr_1673_2024","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T14:05:00Z","timestamp":1751292300000},"page":"449-460","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis"],"prefix":"10.25259","volume":"161","author":[{"given":"Bhavani Perumal","family":"Kannabiran","sequence":"first","affiliation":[{"name":"Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Arthanari","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhin","family":"Bhaskar","sequence":"additional","affiliation":[{"name":"Department of Statistics, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh Kumar Sathya","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeberk Raja","family":"Inbaraj","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"10.25259\/IJMR_1673_2024\/ref-2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1164\/ajrccm.149.5.8173779","article-title":"Treatment of tuberculosis and tuberculosis infection in adults and children American thoracic society and the centers for disease control and prevention","volume":"149","author":"Bass","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.25259\/IJMR_1673_2024\/ref-3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1378\/chest.108.6.1690","article-title":"Institutional control measures for tuberculosis in the era of multiple drug resistance: ACCP\/ATS consensus conference","volume":"108","author":"Bates","year":"1995","journal-title":"Chest J"},{"key":"10.25259\/IJMR_1673_2024\/ref-4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nrmicro2797","article-title":"Global tuberculosis control: Lessons learnt and future prospects","volume":"10","author":"Lienhardt","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.25259\/IJMR_1673_2024\/ref-5","first-page":"367","article-title":"Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis","volume":"123","author":"Dickinson","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/tmi.13824","article-title":"Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis participants on a newly introduced daily dose regimen in South India: A cross-sectional study","volume":"27","author":"Thamineni","year":"2022","journal-title":"Trop Med Int Health"},{"key":"10.25259\/IJMR_1673_2024\/ref-8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/INF.0000000000001069","article-title":"Low serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status","volume":"35","author":"Ramachandran","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.25259\/IJMR_1673_2024\/ref-9","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/IJMR_1673_2024\/ref-10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: A multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis a randomized controlled trial","volume":"198","author":"Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.25259\/IJMR_1673_2024\/ref-13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.5588\/ijtld.15.0577","article-title":"A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis","volume":"20","author":"Jindani","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-14","doi-asserted-by":"crossref","first-page":"ofae034","DOI":"10.1093\/ofid\/ofae034","article-title":"Safety and efficacy of 25 mg\/kg and 35 mg\/kg vs.10 mg\/kg rifampicin in pulmonary TB: A phase IIb randomized controlled trial","volume":"11","author":"Perumal Kannabiran","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-15","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: A systematic review","volume":"15","author":"Steingart","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-17","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cmi.2021.03.031","article-title":"Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: A systematic review and meta-analysis","volume":"27","author":"Onorato","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.25259\/IJMR_1673_2024\/ref-18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/thx.45.5.403","article-title":"Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations of the joint tuberculosis committee of the British thoracic society","volume":"45","author":"Joint","year":"1990","journal-title":"Thorax"},{"key":"10.25259\/IJMR_1673_2024\/ref-19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.25259\/IJMR_1673_2024\/ref-21","article-title":"Chapter 12: Synthesizing and presenting findings using other methods","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)","author":"McKenzie","year":"2022"},{"key":"10.25259\/IJMR_1673_2024\/ref-22","doi-asserted-by":"crossref","first-page":"EVIDoa2300054","DOI":"10.1056\/EVIDoa2300054","article-title":"Four-month high-dose rifampicin regimens for pulmonary tuberculosis","volume":"2","author":"Jindani","year":"2023","journal-title":"NEJM Evid"},{"key":"10.25259\/IJMR_1673_2024\/ref-23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.51847\/PLywKP28YD","article-title":"Hepatic safety on high dose rifampicin for tuberculosis treatment in TB\/HIV co infected patients: A randomized clinical trial","volume":"12","author":"Sanni","year":"2021","journal-title":"Arch Pharm Pract"},{"key":"10.25259\/IJMR_1673_2024\/ref-24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5588\/ijtld.19.0063","article-title":"First line tuberculosis treatment with well double dose rifampicin is well tolerated","volume":"24","author":"Maug","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-25","doi-asserted-by":"crossref","first-page":"e01054","DOI":"10.1128\/AAC.01054-17","article-title":"Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis","volume":"61","author":"Aarnoutse","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/IJMR_1673_2024\/ref-26","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/jac\/dkz557","article-title":"Effect of high-dose rifampicin on efavirenz pharmacokinetics: Drug\u2013drug interaction randomized trial","volume":"75","author":"Atwine","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.25259\/IJMR_1673_2024\/ref-31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"10.25259\/IJMR_1673_2024\/ref-32","doi-asserted-by":"crossref","first-page":"72S","DOI":"10.1111\/j.1365-2672.1996.tb04835.x","article-title":"Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease","volume":"25","author":"Mitchison","year":"1996","journal-title":"Soc Appl Bacteriol Symp Ser"},{"key":"10.25259\/IJMR_1673_2024\/ref-33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","article-title":"Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months","volume":"147","author":"Mitchison","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-34","doi-asserted-by":"crossref","first-page":"e02464","DOI":"10.1128\/AAC.02464-16","article-title":"Factors Influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India","volume":"61","author":"Ramachandran","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/IJMR_1673_2024\/ref-35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: A no pen-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/cpt.202","article-title":"Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children","volume":"98","author":"Savic","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.25259\/IJMR_1673_2024\/ref-37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","article-title":"Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials","volume":"71","author":"Svensson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.25259\/IJMR_1673_2024\/ref-38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF03041486","article-title":"HIV infection and sputum-culture conversion in patients diagnosed with Mycobacterium tuberculosis: A population-based study","volume":"115","author":"Aliyu","year":"2003","journal-title":"Wien Klin Wochenschr"},{"key":"10.25259\/IJMR_1673_2024\/ref-39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12890-021-01483-w","article-title":"Sputum smear conversion and associated factors among smear-positive pulmonary tuberculosis patients in East Gojjam ZONE, Northwest Ethiopia: A longitudinal study","volume":"21","author":"Asemahagn","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.25259\/IJMR_1673_2024\/ref-40","first-page":"DC09","article-title":"Comparison of LJ medium and BACTEC MGIT 960 culture system for the diagnosis of tuberculosis","volume":"14","author":"Kumari","year":"2020","journal-title":"J Clin Diagnostic Res"},{"key":"10.25259\/IJMR_1673_2024\/ref-41","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"54","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/efficacy-safety-of-high-dose-rifampicin-in-pulmonary-tuberculosis-a-systematic-review-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/efficacy-safety-of-high-dose-rifampicin-in-pulmonary-tuberculosis-a-systematic-review-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T14:05:04Z","timestamp":1751292304000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/efficacy-safety-of-high-dose-rifampicin-in-pulmonary-tuberculosis-a-systematic-review-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":33,"alternative-id":["10.25259\/IJMR_1673_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_1673_2024","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"article-number":"449"}}